FLORHAM PARK, N.J., Aug. 29 /PRNewswire/ -- Today PharmaDerm, a division of Nycomed US, announced the launch of KEROL ZX and KEROL Emulsion to the dermatology and podiatry markets. These specialty products have been developed for improved treatment of dry skin and damaged nails:
-- KEROL Emulsion (NDC#10337-646-10) is supplied in a 10oz. tube for application to larger skin surface areas.
-- KEROL ZX (NDC#10337-644-97) is now supplied in a 12 mL. pre-filled applicator to deliver targeted relief to smaller areas such as nails, corns, and calluses.
The KEROL products are indicated for debridement and promotion of normal healing of hyperkeratotic surface lesions and contain a zinc undecylate and lactic acid vehicle. They work by gently dissolving the intercellular matrix, resulting in the loosening of the horny outer layer of skin, and revealing healthy skin. They are indicated for hyperkeratotic conditions such as dry rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses and damaged and devitalized nails.
“This is an exciting time at PharmaDerm as we build the only fully integrated dermatology company in the U.S.,” said David Fink, General Manager, PharmaDerm and Senior Vice President, Nycomed US. “The KEROL family of products continues to evolve and improve. These new KEROL products provide physicians and patients with a continuum of new treatment options for dry skin and damaged nails.”
About PharmaDerm
PharmaDerm, a division of Nycomed US, is a specialty pharmaceutical company dedicated to developing and commercializing prescription products to treat diseases and conditions of the skin-the largest organ of the human body. Our goal is to pursue development of products that will help improve the lives of patients with skin disease.
Nycomed US is a leading manufacturer of topical prescription products pharmaceutical products in the United States and is uniquely positioned as a fully integrated specialty pharmaceutical company dedicated to skin disease with in-house expertise and facilities for formulation development, clinical development, manufacturing, distribution, sales and marketing.
KEROL(TM) Emulsion and KEROL(TM) ZX are for external use only. Avoid contact with eyes, lips or mucous membranes. Transient stinging, burning, itching or irritation may occur and normally disappear on discontinuing the medication.
CONTACT: Angie Malone of HLD Public Relations, +1-516-536-2020,
amalone@hldpr.com, for PharmaDerm
Web site: http://www.pharmaderm.com/
